1-7 of 7
Daniel H. Albert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Synergistic Effect of Venetoclax Combined with a CDK9 Inhibitor in Primary Diffuse Large B Cell Lymphoma and Follicular Lymphoma Cells

Xiaoxian Zhao, PhD, Darren C. Phillips, PhD, Andrew J. Souers, PhD, Juraj Bodo, PhD, Paul Tapang, Daniel H Albert, PhD, Lisa Durkin, Eric D. Hsi, MD
Journal: Blood
Blood (2015) 126 (23): 2746.
https://doi.org/10.1182/blood.V126.23.2746.2746
Published: 2015
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Guillermo Garcia-Manero, MD, Raoul Tibes, MD, Yi-Lin Chiu, PhD, Hao Xiong, PhD, Qin Qin, Peter Ansell, PhD, Daniel H. Albert, PhD, BSc, Chris Tse, PhD, Brian Oliver, Karim Sajwani, MS, Mark D. McKee, MD, Justin L. Ricker, MD, PhD, H. Jean Khoury, MD
Journal: Blood
Blood (2012) 120 (21): 2617.
https://doi.org/10.1182/blood.V120.21.2617.2617
Published: 2012
Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen
Journal: Blood
Blood (2009) 113 (17): 4052–4062.
https://doi.org/10.1182/blood-2008-05-156422
Published: 2009
Includes: Supplemental data
Journal Articles

Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis and Inhibition of Proliferation of Ba/F3 FLT-3 ITD Mutant Cells.

Jenny E. Hernandez, BS, Junling Li, Ru-Qi Wei, Paul Tapang, Steven K. Davidsen, PhD, Daniel H. Albert, PhD, Patrick A. Marcotte, PhD, Keith B. Glaser, PhD, Cecilia Fu, M.D., Kathleen M. Sakamoto, M.D. PhD.
Journal: Blood
Blood (2007) 110 (11): 1589.
https://doi.org/10.1182/blood.V110.11.1589.1589
Published: 2007
Journal Articles

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Jianbiao Zhou, MD, MSc, Chonglei Bi, B.S., Lai Fong Poon, B.S., Viraj J. Janakakumara, B.S., Jiaying Khng, Hanry Yu, Ph.D., Keith B. Glaser, Ph.D., Daniel H. Albert, Ph.D., Davidsen K. Davidsen, Ph.D., Chien-Shing Chen, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 2367.
https://doi.org/10.1182/blood.V110.11.2367.2367
Published: 2007
Journal Articles

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia

Deepa B. Shankar, Junling Li, Paul Tapang, J. Owen McCall, Lori J. Pease, Yujia Dai, Ru-Qi Wei, Daniel H. Albert, Jennifer J. Bouska, Donald J. Osterling, Jun Guo, Patrick A. Marcotte, Eric F. Johnson, Niru Soni, Kresna Hartandi, Michael R. Michaelides, Steven K. Davidsen, Saul J. Priceman, Jenny C. Chang, Katrin Rhodes, Neil Shah, Theodore B. Moore, Kathleen M. Sakamoto, Keith B. Glaser
Journal: Blood
Blood (2007) 109 (8): 3400–3408.
https://doi.org/10.1182/blood-2006-06-029579
Published: 2007
Includes: Supplemental data